These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34162033)

  • 1. Growth hormone treatment and bone mineral density in pediatric patients with Prader-Willi syndrome.
    Oto Y; Murakami N; Inoue T; Matsubara K; Saima S; Ogata H; Ihara H; Nagai T; Matsubara T
    J Pediatr Endocrinol Metab; 2021 Sep; 34(9):1181-1184. PubMed ID: 34162033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD.
    Jørgensen AP; Ueland T; Sode-Carlsen R; Schreiner T; Rabben KF; Farholt S; Høybye C; Christiansen JS; Bollerslev J
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E753-60. PubMed ID: 23436915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
    de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of growth hormone treatment in children with Prader-Willi syndrome over a 30-year period: a single tertiary center experience.
    Gamage DS; Ambler G; Chan A; Srinivasan S; Maguire AM; Cho YH
    J Pediatr Endocrinol Metab; 2024 Aug; 37(8):680-685. PubMed ID: 39089289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthropometric adjustments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi syndrome.
    Hangartner TN; Short DF; Eldar-Geva T; Hirsch HJ; Tiomkin M; Zimran A; Gross-Tsur V
    Osteoporos Int; 2016 Dec; 27(12):3457-3464. PubMed ID: 27377921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    Grootjen LN; Rutges JPHJ; Damen L; Donze SH; Juriaans AF; Kerkhof GF; Hokken-Koelega ACS
    Eur J Endocrinol; 2021 May; 185(1):47-55. PubMed ID: 33886496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulated GH levels during the transition phase in Prader-Willi syndrome.
    Grugni G; Marzullo P; Delvecchio M; Iughetti L; Licenziati MR; Osimani S; Ragusa L; Salvatoni A; Sartorio A; Stagi S; Crinò A;
    J Endocrinol Invest; 2021 Jul; 44(7):1465-1474. PubMed ID: 33095904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC;
    J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density during 3 years of growth hormone in previously GH-treated young adults with PWS.
    Damen L; Grootjen LN; Donze SH; de Graaff LCG; van der Velden JAEM; Hokken-Koelega ACS
    Eur J Endocrinol; 2021 May; 184(6):773-782. PubMed ID: 33769952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
    Oto Y; Tanaka Y; Abe Y; Obata K; Tsuchiya T; Yoshino A; Murakami N; Nagai T
    Am J Med Genet A; 2014 Mar; 164A(3):671-5. PubMed ID: 24443368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on body composition and bone density in children with Prader-Willi syndrome.
    Rubin DA; Cano-Sokoloff N; Castner DL; Judelson DA; Wright P; Duran A; Haqq AM
    Horm Res Paediatr; 2013; 79(5):271-6. PubMed ID: 23615452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle-bone characteristics in children with Prader-Willi syndrome.
    Edouard T; Deal C; Van Vliet G; Gaulin N; Moreau A; Rauch F; Alos N
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E275-81. PubMed ID: 22162467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.